I read this: “In past releases, we have discu
Post# of 72440
Posted On: 02/22/2016 12:17:28 PM
I read this:
“In past releases, we have discussed disease stabilization and reduction of cancerous lesions in some patients treated with Kevetrin,” said Leo Ehrlich, Chief Executive Officer at Cellceutix. “Now, this new p21 data only reinforces our high expectations for and confidence in Kevetrin, specifically, its potential to treat patients across a broad spectrum of cancer types and even those in late stages with refractory tumors. It is exciting to see our early clinical work in the lab translating to the bedside.”
And I hear "Rosen et all shorts, f' you and your frivolous lawsuit! again!"
“In past releases, we have discussed disease stabilization and reduction of cancerous lesions in some patients treated with Kevetrin,” said Leo Ehrlich, Chief Executive Officer at Cellceutix. “Now, this new p21 data only reinforces our high expectations for and confidence in Kevetrin, specifically, its potential to treat patients across a broad spectrum of cancer types and even those in late stages with refractory tumors. It is exciting to see our early clinical work in the lab translating to the bedside.”
And I hear "Rosen et all shorts, f' you and your frivolous lawsuit! again!"
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
Scroll down for more posts ▼